Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials
Pooled result · HbA1c reductionResult — go to the resultMD −0.17 % 95% CI −0.28 to −0.06Authors' conclusion
Once-weekly insulin icodec showed a better HbA1c reduction with a higher proportion of patients achieving HbA1c targets in comparison with once-daily basal insulin analogues. They were no major safety concerns with respect to hypoglycaemia or adverse events.
Study context
- Population
- Patients with T2D in RCTs comparing insulin icodec vs other insulin analogues; databases screened until July 2023
- Participants
- 3,764 patients5 RCTs
- Comparison
- Once-weekly insulin icodec vs other basal insulin analogues
- Outcome
- HbA1c reduction
Methodological detailsPRISMA, phase 3 ONWARDS trials
- PRISMA
- Phase 3 ONWARDS trials
Pooled result
As reported in the abstract
MD
−0.17 %
95% CI −0.28 to −0.06
P = 0.003
Insulin icodecvs Comparator
MD −0.17 % (95% CI −0.28 to −0.06); P = 0.003
Further pooled results
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| HbA1c <7% achieved | 1.51 (1.14–1.99) | P = 0.004 | |
| HbA1c <7% without hypoglycaemia | 1.45 (1.26–1.67) | P < 0.00001 | |
| 0.512Odds ratio (log scale) |
| Outcome | MD (%) (95% CI) | P value | |
|---|---|---|---|
| TIRComparatively similar | 2.42 (0.01–4.84) | P = 0.05 | |
| −20246Difference, % (linear scale) |
FPG
- No significant difference in FPG vs other insulin analogues
Efficacy by comparator (subgroup analysis)
- Insulin icodec had similar efficacy vs glargine U100
- Insulin icodec had superior efficacy, with higher HbA1c reduction, vs degludec
Safety
Hypoglycaemia
- Significantly higher incidence of level 1 hypoglycaemia with insulin icodec
- No significant difference in levels 2, 3 and combined 2/3 hypoglycaemia
Adverse events
- Any AEs and AEs related to basal insulin comparably similar with insulin icodec and comparators
Safety by comparator (subgroup analysis)
- Safety comparable between insulin icodec and glargine U100
- Higher incidence of hypoglycaemia events and any AEs with insulin icodec vs degludec
Original publication
Efficacy and safety of once‐weekly insulin icodec in type 2 diabetes: A meta‐analysis of ONWARDS phase 3 randomized controlled trials. Diabetes Obes Metab. Published 8 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →